An accurate fully automated panel of plasma biomarkers for Alzheimer's disease

Abstract Introduction There is a great need for fully automated plasma assays that can measure amyloid beta (Aβ) pathology and predict future Alzheimer's disease (AD) dementia. Methods Two cohorts ( n = 920) were examined: Panel A+ ( n = 32 cognitively unimpaired [CU], n = 106 mild cognitive impairment [MCI], and n = 89 AD) and BioFINDER‐1 ( n = 461 CU, n = 232 MCI). Plasma Aβ42/Aβ40, phosphorylated tau (p‐tau)181, two p‐tau217 variants, ApoE4 protein, neurofilament light, and GFAP were measured using Elecsys prototype immunoassays. Results The best biomarker for discriminating Aβ‐positive versus Aβ‐negative participants was Aβ42/Aβ40 (are under the curve [AUC] 0.83–0.87). Combining Aβ42/Aβ40, p‐tau181, and ApoE4 improved the AUCs significantly (0.90 to 0.93; P < 0.01). Adding additional biomarkers had marginal effects (ΔAUC ≤0.01). In BioFINDER, p‐tau181, p‐tau217, and ApoE4 predicted AD dementia within 6 years in CU (AUC 0.88) and p‐tau181, p‐tau217, and Aβ42/Aβ40 in MCI (AUC 0.87). Discussion The high accuracies for Aβ pathology and future AD dementia using fully automated instruments are promising for implementing plasma biomarkers in clinical trials and clinical routine.